Compare INTG & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTG | CSBR |
|---|---|---|
| Founded | 1965 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 83.5M |
| IPO Year | 1995 | 2015 |
| Metric | INTG | CSBR |
|---|---|---|
| Price | $41.04 | $6.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 13.6K | 6.1K |
| Earning Date | 05-13-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 161.11 |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $74,753,000.00 | $2,900,000.00 |
| Revenue This Year | N/A | $4.84 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | $56.91 | ★ N/A |
| Revenue Growth | ★ 4.43 | N/A |
| 52 Week Low | $10.37 | $5.50 |
| 52 Week High | $43.84 | $9.63 |
| Indicator | INTG | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 60.18 | 44.80 |
| Support Level | $29.93 | $5.60 |
| Resistance Level | $42.48 | $6.31 |
| Average True Range (ATR) | 2.55 | 0.25 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 74.43 | 14.27 |
The Intergroup Corp is a company operating in the real estate sector. It was formed to buy, develop, operate, rehabilitate, and dispose of real property of various types and descriptions, as well as to engage in other related business and investment activities. The company operates through three segments: Hotel, Real Estate, and Investment Transactions. The Hotel Operations segment, which generates the majority of the revenue, covers the operation of the Hilton hotel and garage. The Real Estate Operations segment involves the management of multifamily rental properties, while the Investment Transactions segment includes investments of cash in marketable securities and other assets.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.